Summary
Becton, Dickinson and Company (BDX) reported its 2012 fiscal year-end results, showcasing a global medical technology company with diversified operations across BD Medical, BD Diagnostics, and BD Biosciences segments. Despite a challenging global economic environment impacting healthcare utilization and pricing pressures, especially in its Biosciences segment, BD demonstrated revenue growth driven by new product launches and strategic acquisitions, including KIESTRA Lab Automation and Sirigen Group. The company continues to invest in research and development and emerging markets, aligning with its strategy to enhance shareholder value through innovation and operational efficiency. Financially, BD reported revenues of $7.7 billion, a 1.6% increase year-over-year, with solid growth in its Medical and Diagnostics segments. The company maintained a strong financial position with $2.2 billion in cash and equivalents. BD also actively returned capital to shareholders through share repurchases and dividends. Key risks identified include global economic conditions, foreign currency fluctuations, changes in healthcare reimbursement, and the impact of U.S. healthcare reform, notably the impending medical device excise tax. The company is also navigating several significant legal proceedings, including antitrust litigation, which could materially affect its financial results.
Financial Highlights
55 data points| Revenue | $7.71B |
| Cost of Revenue | $3.75B |
| Gross Profit | $3.95B |
| R&D Expenses | $472.00M |
| SG&A Expenses | $1.92B |
| Operating Expenses | $6.15B |
| Operating Income | $1.56B |
| Interest Expense | $135.00M |
| Net Income | $1.17B |
| EPS (Basic) | $5.69 |
| EPS (Diluted) | $5.59 |
| Shares Outstanding (Basic) | 205.46M |
| Shares Outstanding (Diluted) | 209.18M |
Key Highlights
- 1BD reported total revenues of $7.7 billion for fiscal year 2012, a 1.6% increase from the prior year, driven by volume increases and strategic acquisitions.
- 2The company's three segments (Medical, Diagnostics, Biosciences) all contributed to revenue growth, with Medical and Diagnostics showing particular strength from new products and acquisitions.
- 3BD made strategic acquisitions during the year, purchasing KIESTRA Lab Automation for $59 million and Sirigen Group for $64 million to enhance its lab automation and flow cytometry offerings.
- 4Research and development spending remained robust at $472 million, reflecting BD's commitment to innovation and new product development across its segments.
- 5The company ended the fiscal year with a strong liquidity position, holding $2.2 billion in cash and short-term investments.
- 6BD actively managed its capital structure, repurchasing $1.5 billion of its common stock and paying $368 million in dividends during fiscal year 2012.
- 7Significant legal proceedings, including antitrust litigation, are ongoing and pose a potential risk to the company's financial condition.